Welcome to BioSeeker Group!

Triple Analysis: Pancreatic Cancer, Protein Kinase Inhibitors and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5056
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Pancreatic Cancer, Protein Kinase Inhibitors and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Protein Kinase Inhibitors and Peptides.

    To find out more about Triple Analysis: Pancreatic Cancer, Protein Kinase Inhibitors and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Protein Kinase Inhibitors and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part II: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
4SC
7TM Pharma
AB Science
Abbott
Abiogen
Acceleron Pharma
ACT Biotech
Active Biotech
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affymax
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alethia Biotherapeutics
Allist Pharmaceuticals
Allostera
Allosterix
AlphaVax
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Anza Therapeutics
AplaGen Biopharmaceuticals
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Ardana
Ardea Biosciences
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Avila Therapeutics
Bavarian Nordic
Baxter International
Bayer
Benitec
Berkeley Lab
Betapharma
Bio-Path Holdings
BioAxone
Biogen Idec
Biokine Therapeutics
Bionovo
BioNumerik
BioSante
Biotecnol
Biotica Technology
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Callisto Pharmaceuticals
Cambrex
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
Catalyst Biosciences
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CerRx
CG Therapeutics
Chemokine Therapeutics
Chiasma
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
Clinical Data
Clinuvel
CompleGen
Compugen
CoNCERT Pharmaceuticals
Cornerstone Pharmaceuticals
CritiTech
Curaxis
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokine PharmaSciences
Cytokinetics
Cytopia
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Digna Biotech
Dongkook Pharm
Dyax
EGEN Inc
Eisai
Elara Pharmaceuticals
Eli Lilly
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Erimos
Esperance Pharmaceuticals
Exelixis
FibroGen
Formula Pharmaceuticals
Galapagos
Galectin Therapeutics
Galena Biopharma
Generex
GENova Biotherapeutics
Genovax
Genta
GenVec
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
GP Pharm
GPC Biotech
Gryphon Therapeutics
Hanmi
Hoffmann-La Roche
Human Genome Sciences
Hutchison China MediTech
Hypha Discovery
Idera Pharmaceuticals
ImClone Systems
ImmunoCellular Therapeutics
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Immutep
Incozen Therapeutics
Incyte Corporation
Inhibiton Therapeutics
Innate Pharma
Innovive
Inovio
Insmed
Insys Therapeutics
Intellikine
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAEL-GemVax
KAI Pharmaceuticals
KaloBios
Kalypsys
Karus Therapeutics
Karyon-CTT
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirax
Kirin Pharma
KuDOS
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
Lexicon Pharmaceuticals
Ligand
Marillion Pharmaceuticals
Marina Biotech
MaxoCore Pharmaceuticals
MBiotec
Meda
MediGene
Mediolanum
Medisyn Technologies
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Molecular LogiX
MolMed
Myrexis
Nano Terra
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
NexusPharma
NicOx
Nidus Laboratories
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novogen
NPS Pharmaceuticals
Oncalis
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Pathway Therapeutics
Patrys
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Phoenix Biotechnology
PHusis Therapeutics
Pieris
Pierre Fabre
Piramal
PIramed
Portola Pharmaceuticals
Proacta
Progenics Pharmaceuticals
ProMetic Life Sciences
Protagonist
Protgen
Provid
Q Chip
QLT
Quantum Pharmaceuticals
Raptor Pharmaceutical
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samtheo Biopharma
Samyang
Sanofi
Santaris Pharma
Sarepta Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
Schering-Plough
SciClone Pharmaceuticals
Selvita
Semafore Pharmaceuticals
Sentinel Oncology
Serometrix
SGX Pharmaceuticals
Shire
Silence Therapeutics
Soligenix
Spectrum Pharmaceuticals
Sunesis
SuperGen
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Tau Therapeutics
TauTaTis
TCD Pharma
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tragara Pharmaceuticals
TransTech Pharma
Trion Pharma
UCB
UMN Pharma
Unigene
United Biomedical
VasGene Therapeutics
Vaxil BioTherapeutics
Vaxon Biotech
VaxOnco
Velacor Therapeutics
Vernalis
Vertex Pharmaceuticals
Wilex
Vion Pharmaceuticals
VioQuest
ViroMed
Wyeth
Xcovery
Xencor
Xerion
Xigen
Yakult Honsha
YM BioSciences
Zelos Therapeutics
Zensun
Zenyaku Kogyo
Zeria
A Shortlist of Drugs Included are:
A6
abarelix
ABT-510
AC-480
AE-37
AEG-35156
AEZS-108
AF-802
afamelanotide
afatinib
aflibercept
AGS-1C4D4
alvocidib
AMG-386
angiopep+paclitaxel
Angiozyme
apatinib
apricoxib
AR-42
ARC-100
ARQ-197
AT-7519
AT-9283
axitinib
AZD-8055
AZD-8931
bafetinib
barasertib
bardoxolone methyl
bevacizumab
BEZ-235
BGT-226
BI-811283
BIBF-1120
BMS-690514
BMS-754807
BMS-777607
bosutinib
brivanib alaninate
brivudine
Cabozantinib
CAL-101
capecitabine
catumaxomab
CBP-501
CC-223
cediranib
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
conatumumab
corticorelin acetate
CPI-613
crizotinib
CRLX-101
dacomitinib
dalotuzumab
danusertib
dasatinib
deslorelin
dinaciclib
docetaxel
dovitinib lactate
doxorubicin
E-75
E-7820
emepepimut-S
endoxifen
eniluracil
ENMD-2076
enzastaurin hydrochloride
EP-100
erlotinib
everolimus
foretinib
fostamatinib disodium
FPI-01
ganitumab
gefitinib
goserelin
GSK-1120212
GSK-2118436
GV-1001
GVAX
GX-301
Her-2/Neu peptides
histrelin
IC-83
icotinib hydrochloride
icrucumab
idronoxil
imatinib mesilate
imMucin
IMP-321
INCB-028060
INSM-18
ipilimumab
IPP-204106
irinotecan
irinotecan hydrochloride
ISA-P53-01
JI-101
kahalalide F
KD032
KX2-391
L19-IL2
lanreotide
lapatinib ditosylate
lenvatinib
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
linifanib
linsitinib
LipoVIL12
LY-2090314
masitinib
MDX-1379
MetXia
MGCD-265
midostaurin
MK-1775
MKC-1
MLN-8237
MM-111
mocetinostat
motesanib diphosphate
motexafin gadolinium
MVA-BN Her-2 vaccine
nadroparin
NAFB001
neratinib
netupitant
nilotinib
nimotuzumab
NPB-001-056
oblimersen sodium
octreotide
octreotide, LAR
olaparib
ON-01910
onartuzumab
OSI-027
OTS-102
ozarelix
P-276-00
P276-00
paclitaxel
PancAtak
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
PD-0332991
pegdinetanib
pemetrexed disodium
pentamidine isethionate
perifosine
PHA-848125AC
plitidepsin
polyclonal antibody stimulator
ponatinib
PX-12
PX-866
quinacrine
quizartinib dihydrochloride
RAF-265
ramucirumab
regorafenib
Rexin-G
ridaforolimus
rilotumumab
rindopepimut
romidepsin
romurtide
ruxolitinib
RX-0201
RX-0201-N
SCH-900776
seliciclib
selumetinib
siltuximab
sirolimus
sorafenib tosylate
sotatercept
ß-lapachone
SU-6668
sunitinib malate
Survivac
talmapimod
talminogene laherparepvec
tandutinib
tegafur + uracil
telatinib
temsirolimus
terameprocol
thymalfasin
tigatuzumab
tivozanib
TM-30339
tocilizumab
trabedersen
trastuzumab
triciribine phosphate
TS-1
tucotuzumab celmoleukin
vandetanib
vapreotide, immediate-release
varlitinib
vemurafenib
vismodegib
vitespen
volasertib
volociximab
vosaroxin
VX-001
WX-671
XL-147
XL-281
XL-413
XL-647
XL-765
Z-360

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Protein Kinase Inhibitors and Peptides.
    To find out more about Triple Analysis: Pancreatic Cancer, Protein Kinase Inhibitors and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Protein Kinase Inhibitors and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Lung Cancer and Lymphoma
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lung Cancer and Lymphoma. Learn More


Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology
Assess opportunities and risks for the continued development of anti-angiogenic and vascular targeting agents in five major cancer indications. Learn More

Other selected research from the 'Oncology' category:


Leukemia: Analytical Tool
This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of leukemia. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More


Triple Analysis: Lung Cancer, Melanoma and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More